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(E)-3-(2-chloroquinolin-3-yl)-1-(2-hydroxyphenyl) prop-2-en-1-one and its pyrimidine analogues
e.g. 2-[2-amino-6-(2-chloroquinolin-3-yl)-5,6-dihydropyrimidin-4-yl]phenols have been prepared
by condensation of 2-chloro-3-formyl quinoline with differently substituted 2-hydroxy acetophe-
nones and further treatment with guanidine carbonate. All the newly synthesized compounds have
been evaluated for their in vitro growth inhibitory activity against Escherichia coli, Pseudomonas vul-
garis, Bacillus subtilis, Staphylococcus aureus, Staphylococcus typhi, Candida albicans, Aspergillus
niger and Pseudomonas chrysogenum.
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Extensive research on diverse biological activities of heterocy-
cles has conﬁrmed their immense signiﬁcance in the pathophys-
iology of diseases. The amalgamation of two pharmacologically
important structural scaffolds leads to a new library of hetero-
cycles, possessing a broad spectrum of activities against numer-
ous pathogenic strains and also striking activities against
cancer. We have developed an extensive research program on
the synthesis (Pathan et al., 2011) and biological evaluationsof Chemical Hybrids (as ‘‘Molecular Lego Sets’’) incorporating
a diverse architecture of nuclei within their molecular
framework and to explore synergistic therapeutic relevance as
thrombin inhibitors, prostate speciﬁc antigen inhibitors, and
anticancer drugs. We have exempliﬁed the synthesis of an array
of hybrid molecules: We combined substituted quinolines with
pyrazoline residues in hybrid scaffolds in a single molecular
framework to secure enhanced and systematically attenuated
and accentuated biological activity (Dave and Rahatgaonkar,
2009). Synthesis of hybrid molecules is of interest as a way of
synergistically increasing drug discovery portfolios.
Chalcone derivatives have demonstrated activity of pharma-
ceutical relevance: considerable attention has been lavished on
these moieties. The compounds are of potential therapeutic rel-
evance as anti-bacterial, antifungal, antiviral, anti-parasitic,
anti-cancer, antileishmaniel and anti-tubercular agents (Peters
and Musher, 1937; Crambie and Mistry, 1990; Bratt et al.,
2003). Some chalcones are also known to possess anti-inﬂamma-
tory and analgesic properties. Quinolines and their derivatives
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1998; Dube et al., 1998), anti-ﬁlarial (Tiwari et al., 2000;
Mathew et al., 2010), anti-bacterial (Kidwai et al., 2000; Naik
et al., 2009) and anti-malarial (Ziegler et al., 2001; Chauhan
and Srivastava, 2001; Kaur et al., 2010) activities and addition-
ally, for their cardiovascular (Dong et al., 1992), anti-neoplastic
(Ferlin et al., 2000) and receptor agonist activities (Zhi et al.,
1998).
The unique structural motif of pyrimidine has been used as
a starting point for an elegant design of potential drugs and
novel heterocycles. Pyrimidine containing heterocycles incor-
porating hydroxyl groups are found to play a vital role in bio-
logical processes (Kenner et al., 1944; Bhuiyan et al., 2005) as
well as in synthetic drugs. Different pyrimidine heterocycles
are reported to have various therapeutic activities like anti-
HIV (Noriyuki et al., 2002), anti-tubercular (Jani et al.,
1994), antitumor (Safonova et al., 1999) antineoplastic (Jean-
Damien et al., 2002), anti-inﬂammatory (Nakaguti et al.,
1986), diuretic (Papesh and Schroeder, 1956) and antimalarial
(Tokutake, 1977). Fascinated by such properties, medicinal
chemists expend considerable synthetic efforts to construct
these fascinating scaffolds in a highly efﬁcient fashion by
employing a variety of new elegant strategies. Very few ap-
proaches have been directed at the synthesis of heterocycles
containing both quinoline and pyrimidine nuclei within a sin-
gle molecular framework. Our research encompasses the syn-
thesis of quinoline–pyrimidine hybrids.
We embarked on the synthesis of appropriately substituted
2-[2-amino-6-(2-chloroquinolin-3-yl)-5,6-dihydropyrimidin-4-
yl] phenols by conventional method and synthesized a library
of new quinoline–pyrimidine hybrids 3a–j.
2. Experimental
2.1. General
Melting points were determined by open capillary method and
are uncorrected. All solvents were distilled and dried prior to
use. TLC was performed on silica gel G and the spots were ex-
posed to iodine vapour for visualization. A mixture of benzene
and ethylacetate (7:3) was used as an eluent. 1H NMR and 13C
NMR spectra were recorded in DMSO-d6 on a Brucker AC
400 (MHz) instrument. Chemical shifts are reported in ppm
using TMS as the internal standard. IR spectra were obtainedTable 1 Physical and analytical data of the newly synthesized com
Compound R1 R2 R3 M.P. (C) Yield (%)
3a Cl H H 165 82
3b CH3 H H 205 78
3c Cl H Br 210 84
3d CH3 H Br 152 78
3e Cl H I 238 85
3f CH3 H I 168 80
3g Cl H NO2 288 81
3h CH3 H NO2 250 73
3i Br OCH3 H 130 78
3j I OCH3 H 132 81on a Perkin Elmer 1800 spectrophotometer using KBr discs
and mass spectra were measured with Shimadzu gas chromato-
graph coupled with QP5050 Spectrometer at 1–1.5 eV.
2.2. Microbiology
2.2.1. In vitro antibacterial and antifungal activities
All the newly synthesized compounds were evaluated for their
efﬁcacy against the clinically isolated microorganisms like
Escherichia coli, Pseudomonas vulgaris, Bacillus subtilis,
Staphylococcus aureus, Staphylococcus typhi, Candida albicans,
Aspergillus niger and Pseudomonas chrysogenum.
The preliminary antimicrobial activities of the compounds
3a–j were tested using the cup-plate (Collins, 1967) method.
For compounds 3a–j, the nutrient agar broth was prepared
by aseptic inoculation with 0.5 mL of 24-h-old subcultures of
all the above said microorganisms, in separate ﬂasks at 40–
50 C and mixing well by gentle shaking. About 25 mL of
the contents of the ﬂask was poured, evenly spread in a Petri
dish (13 cm in diameter) and allowed to set for 2 h. Cups
(6 mm in diameter) were made with the help of borer in an
agar medium. The compounds to be tested were dissolved in
DMSO at different concentrations viz. 10 ug/mL, 100 ug/mL,
200 ug/mL and 500 ug/mL; and were ﬁlled in the well made
in Petri dishes with 1 mL of the respective solution.
The plates were incubated at 37 C for 24 h, the control was
similarly maintained with 1 mL of DMSO and the zones of
inhibition of the bacterial and fungal growth were measured
in mm.
The test compounds under investigation were incorporated
into agar, which had previously been inoculated with the test
organisms.
Ampicillin and amphotericin B were used as the standard
drugs. The inoculated plates were incubated at 37 C for
24 h in the case of bacteria and 48 h in the case of fungus.
The zone of inhibition was compared with the standard drugs
(Tables 2 and 3).
The minimum inhibitory concentration (MIC) (Murray
et al., 1995) of the compounds was tested using the microdilu-
tion susceptibility method. The chemical stock solutions of all
the compounds and reference drugs were prepared by dissolv-
ing 1000 ug in 5 mL DMSO. A series of dilutions was prepared
as 500, 200, 100, 10 ug/mL. The culture of microorganism was
inoculated in each dilution. The dilutions were incubated atpounds 3a–j.
Mol. formula Analysis% found (calculated)
C H N
C19H14Cl2N4O 59.06 (59.24) 3.68 (3.66) 14.13 (14.54)
C20H17ClN4O 65.86 (65.84) 4.48 (4.70) 15.23 (15.36)
C19H13BrCl2N4O 49.16 (49.17) 2.66 (2.82) 12.11 (12.07)
C20H16BrClN4O 54.09 (54.14) 3.57 (3.63) 13.17 (12.63)
C19H13Cl2IN4O 44.04 (44.65) 2.32 (2.56) 10.13 (10.96)
C20H16ClIN4O 48.92 (48.95) 3.45 (3.29) 11.56 (11.42)
C19H13Cl2N5O3 52.06 (53.04) 3.05 (3.05) 16.10 (16.28)
C20H16ClN5O3 57.88 (58.61) 3.34 (3.94) 17.09 (17.09)
C20H16BrClN4O2 52.57 (52.25) 3.19 (3.51) 12.21 (12.19)
C20H16ClIN4O2 47.89 (47.41) 3.12 (3.18) 11.17 (11.06)
Table 3 Minimum inhibitory concentration of 3a–j at 200 ug/
mL against clinically isolated C. albicans, A. niger and P.
chrysogenum.
Entry C. albicans A. niger P. chrysogenum
3a – – –
3b – – –
3c – – –
3d – ++ +
3e – – +
3f – – –
3g – – –
3h – – –
3i – – –
3j + + –
Amphotericin B ++++ ++++ ++++
Symbols: zone diameter of growth inhibition: (–) = inactive
(<10 mm); (+) = weakly active (10–15 mm); (++) = moderately
active (16–21 mm); (+++)= highly active (22–28 mm).
Table 2 Minimum inhibitory concentration of 3a–j in ug/mL against clinically isolated S. aureus and P. vulgaris.
Entry S. aureus P. vulgaris
10 100 200 500 App.MIC 10 100 200 500 App. MIC
3a  – + ++ 500  ++ ++ ++ 100
3b  ++ ++ ++ 100  ++ ++ ++ 100
3c  – + ++ 500  ++ ++ ++ 100
3d  ++ ++ ++ 100  ++ ++ ++ 100
3e   + ++ 500  ++ ++ ++ 100
3f   + ++ 500  – + ++ 500
3g  ++ ++ ++ 100  – + ++ 500
3h  – ++ ++ 200  ++ ++ ++ 100
3i  ++ ++ ++ 100  ++ ++ ++ 100
3j  ++ ++ ++ 100  ++ ++ ++ 100
Ampicillin +++ +++ +++ +++ 10 +++ +++ +++ +++ 10
Symbols: (–) = conﬂuent growth (no inhibition), Inactive (<10 mm); (+) = weakly active (10–15 mm); (++) = moderately active (16–
21 mm); (+++) = highly active (22–28 mm).
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The solutions with no turbidity were considered as MIC for
tested compounds.3. General procedure for synthesis of a novel series of differently
substituted 2-[2-amino-6-(2-chloroquinolin-3-yl)-5,6-
dihydropyrimidin-4-yl]phenol (3a–j)
Major precursors of the reaction, i.e. appropriately substituted
(E)-3-(2-chloroquinolin-3-yl)-1-(2-hydroxyphenyl) prop-2-en-
1-ones 2a–j were synthesized as per the reported procedures
(Rahatgaonkar et al., 2009).
To 0.01 mol of chalcone was added 12 mL of EtOH. To
the above reaction mixture was added 0.02 mol of Guani-
dine carbonate and the reaction was further basiﬁed by add-
ing 0.56 g KOH. The solution was reﬂuxed for 4–5 h. After
the reaction when inferred through TLC, was quenched with
water, and the organic compound obtained was then succes-
sively washed with 10 mL 5% solution of HCl and ﬁnallywith 25 mL of water. The organic compound was ﬁltered,
washed, dried and recrystallized to furnish the corresponding
pyrimidines.
3.1. 2-[2-Amino-6-(2-chloroquinolin-3-yl)-5,6-
dihydropyrimidin-4-yl]-4-chlorophenol (3a)
IR (KBr) kmax (cm
1): 3430, 3350; 1H NMR (400 MHz,
DMSO-d6) (d): 6.93 (s, 2H, NH2), 7.21 (m, 3H, CH2–CH),
11.97 (s, 1H, OH), 7.43–8.92 (br m, 8H, aromatic region.);
13C NMR (DMSO-d6) (d: 38.6 (CH2 pyrimidine ring carbon),
41.8 (CH pyrimidine ring carbon), 116.7, 120.1, 126.3, 127.2,
127.4, 128.3, 128.6, 129.8, 132.4, 132.8, 136.5, 138.7, 145.2
(phenyl carbons), 152.2 (C–Cl quinoline ring), 159.3 (C–OH),
163.1 (C–NH2), 165.1 (pyrimidine ring carbon). Mass spec-
trum (GC–MS), m/z 384.
3.2. 2-[2-Amino-6-(2-chloroquinolin-3-yl)-5,6-
dihydropyrimidin-4-yl]-4-methylphenol (3b)
IR (KBr) kmax (cm
1): 3432, 3354; 1H NMR (400 MHz,
DMSO-d6) (d): 2.36 (s, 3H, CH3), 6.82 (s, 2H, NH2), 7.10
(m, 3H, CH2–CH), 11.86 (s, 1H, OH), 7.32–8.81 (br m,
8H, aromatic region.); 13C NMR (DMSO-d6) (d: 24.4
(CH3), 38.4 (CH2 pyrimidine ring carbon), 41.8 (CH pyrim-
idine ring carbon), 115.2, 119.5, 126.7, 128, 128, 128.1,
128.8, 131.2, 131.5, 132.8, 135.8, 139.2, 144.9 (phenyl car-
bons), 151.7 (C–Cl quinoline ring), 159.2 (C–OH), 163.3
(C–NH2), 165.2 (pyrimidine ring carbon). Mass spectrum
(GC–MS), m/z 364.
3.3. 2-[2-Amino-6-(2-chloroquinolin-3-yl)-5,6-
dihydropyrimidin-4-yl]-6-bromo-4-chlorophenol (3c)
IR (KBr) kmax (cm
1): 3430, 3357; 1H NMR (400 MHz,
DMSO-d6) (d): 7.02 (s, 2H, NH2), 7.31 (m, 3H, CH2–CH),
12.00 (s, 1H, OH), 7.54–8.93 (br m, 7H, aromatic region.);
13C NMR (DMSO-d6) (d: 38.3 (CH2 pyrimidine ring carbon),
42.2 (CH pyrimidine ring carbon), 115.9, 119.8, 127.4, 128,
128.2, 128.4, 129.7, 129.9, 131.2, 133.3, 137.1, 139, 144.2 (phe-
nyl carbons), 151.6 (C–Cl quinoline ring), 159.3 (C–OH),
S454 S.S. Dave, A.M. Rahatgaonkar163.4, (C–NH2) 166.5 (pyrimidine ring carbon). Mass spec-
trum (GC–MS), m/z 464.
3.4. 2-[2-Amino-6-(2-chloroquinolin-3-yl)-5,6-
dihydropyrimidin-4-yl]-6-bromo-4-methylphenol (3d)
IR (KBr) kmax (cm
1): 3435, 3362; 1H NMR (400 MHz,
DMSO-d6) (d): 2.36(s, 3H, CH3), 6.90 (s, 2H, NH2), 7.18 (m,
3H, CH2–CH), 11.97 (s, 1H, OH), 7.32–8.81 (br m, 7H, aro-
matic region.); 13C NMR (DMSO-d6) (d: 23.5 (CH3), 39.2
(CH2 pyrimidine ring carbon), 40.7 (CH pyrimidine ring car-
bon), 116.4, 120.4, 126.7, 127.5, 127.9, 128.1, 129.4, 129.5,
131.3, 133.3, 135.8, 138.4, 145.2 (phenyl carbons), 152.1 (C–
Cl quinoline ring), 159.5 (C–OH), 162.8 (C–NH2), 164.6
(pyrimidine ring carbon). Mass spectrum (GC–MS), m/z 442.
3.5. 2-[2-Amino-6-(2-chloroquinolin-3-yl)-5,6-
dihydropyrimidin-4-yl]-4-chloro-6-iodophenol (3e)
IR (KBr) kmax (cm
1): 3435, 3352; 1H NMR (400 MHz,
DMSO-d6) (d): 6.93 (s, 2H, NH2), 7.21 (m, 3H, CH2–CH),
12.27 (s, 1H, OH), 7.43–8.92 (br m, 7H, aromatic region.);
13C NMR (DMSO-d6) (d:39.5 (CH2 pyrimidine ring carbon),
40.7 (CH pyrimidine ring carbon), 88.9, 120.2, 126.5, 128.1,
128.4, 128.5, 129.4, 131.2, 133.2, 135.8, 139.2, 143.6, 147.6
(phenyl carbons), 152.3 (C–Cl quinoline ring), 158.6 (C–OH),
163 (C–NH2), 164.5 (pyrimidine ring carbon). Mass spectrum
(GC–MS), m/z 508.
3.6. 2-[2-Amino-6-(2-chloroquinolin-3-yl)-5,6-
dihydropyrimidin-4-yl]-6-iodo-4-methylphenol (3f)
IR (KBr) kmax (cm
1): 3437, 3352; 1H NMR (400 MHz,
DMSO-d6) (d): 2.36 (s, 3H, CH3), 6.85(s, 2H, NH2), 7.13 (m,
3H, CH2–CH), 12.16 (s, 1H, OH), 7.32–8.81 (br m, 7H, aro-
matic region.); 13C NMR (DMSO-d6) (d:23.5 (CH3), 39.6
(CH2 pyrimidine ring carbon), 40.4 (CH pyrimidine ring car-
bon), 87.6, 120.1, 125.8, 127.5, 127.9, 128.1, 129.4, 131.2,
133.4, 135.2, 138.8, 144.9, 146.7 (phenyl carbons), 154.1 (C–
Cl quinoline ring), 159.3 (C–OH), 162.7 (C–NH2), 165.2
(pyrimidine ring carbon). Mass spectrum (GC–MS), m/z 488.
3.7. 2-[2-Amino-6-(2-chloroquinolin-3-yl)-5,6-
dihydropyrimidin-4-yl]-4-chloro-6-nitrophenol (3g)
IR (KBr) kmax (cm
1): 3433, 3355; 1H NMR (400 MHz,
DMSO-d6) (d): 6.99 (s, 2H, NH2), 7.31 (m, 3H, CH2–CH),
13.58 (s, 1H, OH), 7.54–8.92 (br m, 7H, aromatic region.);
13C NMR (DMSO-d6) (d:39.3 (CH2 pyrimidine ring carbon),
40.3 (CH pyrimidine ring carbon), 120.8, 122.4, 124.4, 124.8,
125.2, 127.2, 127.8, 128.9, 132.1 (phenyl carbons), 137.5 (C–
NO2), 138.2, 139.8, 144.4 (phenyl carbons), 150.8 (C–OH),
152.7 (C–Cl quinoline ring), 162.8 (C–NH2), 164.5 (pyrimidine
ring carbon). Mass spectrum (GC–MS), m/z 429.
3.8. 2-[2-Amino-6-(2-chloroquinolin-3-yl)-5,6-
dihydropyrimidin-4-yl]-4-methyl-6-nitrophenol (3h)
IR (KBr) kmax (cm
1): 3433, 3350; 1H NMR (400 MHz,
DMSO-d6) (d): 2.58 (s, 3H, CH3), 6.92 (s, 2H, NH2), 7.20(m, 3H, CH2–CH), 12.98 (s, 1H, OH), 7.43–8.92 (br m, 7H,
aromatic region.); 13C NMR (DMSO-d6) (d:23.6 (CH3), 39
(CH2 pyrimidine ring carbon), 40.3 (CH pyrimidine ring car-
bon), 119.6, 122.4, 124.5, 124.8, 126.4, 127.4, 130.2, 131.8,
133.1, 136.5 (phenyl carbons), 137.4 (C–NO2), 138.8, 145.4
(phenyl carbons), 148.9 (C–OH), 152.6 (C–Cl quinoline ring),
162.7 (C–NH2), 164.5 (pyrimidine ring carbon). Mass spec-
trum (GC–MS), m/z 409.
3.9. 2-[2-amino-6-(2-chloroquinolin-3-yl)-5,6-
dihydropyrimidin-4-yl]-4-bromo-5-methoxy phenol (3i)
IR (KBr) kmax (cm
1): 3430, 3351; 1H NMR (400 MHz,
DMSO-d6) (d): 3.75 (s, 3H, OCH3), 6.79 (s, 2H, NH2), 7.07
(m, 3H, CH2–CH), 11.98 (s, 1H, OH), 7.29–8.78 (br m, 7H,
aromatic region.); 13C NMR (DMSO-d6) (d: 39.2 (CH2 pyrim-
idine ring carbon), 40.2 (CH pyrimidine ring carbon), 56.7
(OCH3), 104.2, 105.2, 113.1, 123.4, 125.2, 125.6, 125.8, 127.4,
130.4, 135.1, 137, 145.1, 152.7 (C–Cl quinoline ring), 160.6
(C–OCH3), 161.8 (C–OH), 163.5 (C–NH2), 166.2 (pyrimidine
ring carbon). Mass spectrum (GC–MS), m/z 458.
3.10. 2-[2-Amino-6-(2-chloroquinolin-3-yl)-5,6-
dihydropyrimidin-4-yl]-4-iodo-5-methoxyphenol (3j)
IR (KBr) kmax (cm
1): 3430, 3356; 1H NMR (400 MHz,
DMSO-d6) (d): 3.74 (s, 3H, OCH3), 6.82 (s, 2H, NH2), 7.11
(m, 3H, CH2–CH), 11.97 (s, 1H, OH), 7.17–8.82 (br m, 7H,
aromatic region.); 13C NMR (DMSO-d6) (d: 39.4 (CH2 pyrim-
idine ring carbon), 40.5 (CH pyrimidine ring carbon), 56.5
(OCH3), 78.5, 101.8, 114.5, 123.1, 125.2, 127.6, 128.2, 129.7,
130.5, 134.4, 138.8, 143.3, 152.4 (C–Cl quinoline ring), 160.7
(C–OCH3), 162.5 (C–OH), 163.9 (C–NH2), 165.7. Mass spec-
trum (GC–MS), m/z 504.4. Result and discussion
The appropriately substituted 2-[2-amino-6-(2-chloroquinolin-
3-yl)-5,6 dihydropyrimidin-4-yl]phenol 3a–j were prepared by
condensing differently substituted (E)-3-(2-chloroquinolin-3-
yl)-1-(2-hydroxyphenyl) prop-2-en-1-ones 2a–j with guanidine
carbonate in the presence of ethanolic potassium hydroxide
as depicted in Scheme 1. Table 1.
Our initial efforts focused on delineating a one pot Claisen
Schmidt condensation of the series of (E)-3-(2-chloroquinolin-
3-yl)-1-(2-hydroxyphenyl) prop-2-en-1-ones 2a–j via cyclocon-
densation of differently substituted 2-hydroxy acetophenones
with 2-chloro-3-formyl quinoline (Meth-Cohn and Taylor,
1995) in ethanol. All permutations generated by varying
parameters, such as concentration of NaOH (1–3 equivalents),
reaction time for cyclocondensation (10–24 h), stirring after
the addition of strong base to reaction mixture (1–4 h), reac-
tion temperature (Room temperature to boiling hot ethanol)
did not lead to higher yields. Numerous experiments aimed
at efﬁcient synthesis of (E)-3-(2-chloroquinolin-3-yl)-1-(2-
hydroxyphenyl) prop-2-en-1-ones 2a–j were frustratingly
unsuccessful. The yields were drastically low and the isolation
procedures were tedious and cumbersome. After extensive
experimentation, we developed an efﬁcient synthesis of (E)-3-
(2-chloroquinolin-3-yl)-1-(2-hydroxyphenyl) prop-2-en-1-ones
Scheme 1 Synthesis of Quinoline scaffold derived chalcones 2a–j and their pyrimidine derivatives 3a–j.
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tended reaction times, difﬁculties in product isolation). The
reaction, after suitable modiﬁcations has been fairly well opti-
mized at 4 C.
The formation of 2a–j could be explained by simple unsub-
stituted 2-chloro-3-formyl quinoline showing less reactivity as
compared to other aromatic aldehydes. Generally different
aromatic aldehydes undergo Claisen Schmidt involving nucle-
ophilic addition reaction; in the present case the quinoline moi-
ety constitutes an electron rich nucleus with a slightly
deactivated –CHO centre, making the molecule more stable
but less reactive. The directly attached chlorine atom helps
the reaction. Under such conditions, acetophenones having
electron donating substituents encounter many reactivity prob-
lems while those with electron withdrawing groups like nitro,
chloro, bromo, iodo attenuate the reaction efﬁciently in the
forward direction with high yields.
To obtain the desired compounds 3a–j in optimal yields,
various conditions were tried for the condensation of appropri-
ately substituted substrates 2-[2-amino-6-(2-chloroquinolin-3-
yl)-5,6-dihydropyrimidin-4-yl] phenol 3a–j with guanidine car-
bonate in DMF, ethylene glycol and ethanol/KOH. Ethanol
was found to be the most suitable solvent to secure the highest
yields.
4.1. Compound characterization
The IR spectra of compounds 3a–j showed two peaks: one
broad and another sharp at 3430 and 3350 cm1 due to –
NH2 function and phenolic OH respectively. Absence of char-
acteristic absorption bands for C‚O in 3a and appearance of
other peaks at 1541, 1581 and 1664 supported the assigned
structure.
The 1H NMR spectra of compounds 3a–j displayed an
additional signal at 6.89 ppm due to two protons derived from
–NH2 attached to the pyrimidine moiety. Interestingly, a uni-
form pattern of multiplets ranging from 7.2 to 8.9 ppm was ob-
served in the 1H NMR spectra of all the compounds 3a–j
assigned the protons of aromatic rings, strongly supported
the structures.
In addition, –CH3 group of compounds 3b, 3d, 3f, 3h
resonated at 2.3 ppm integrating for three protons as a singlet
in the 1H NMR spectrum of each compound, respectively.Moreover, the signals derived from –OCH3 group in com-
pound 3i and 3j were recorded at 3.75 ppm integrating three
protons, respectively. The singlets ranging from 11.97 to
13.58 ppm were observed for the phenolic –OH group of the
respective compounds 3a–j.
13C NMR spectrum of compound 3a showed aromatic res-
onances at 38.6, 41.8 ppm for pyrimidine carbon atoms. The
peak corresponding to the –OCH3 at 56.5 ppm of 3i and 3j
supported the assigned structure. The compounds 3a–j re-
vealed peaks at 163 ppm suggesting the presence of –C–NH2
of pyrimidine ring.
The elemental analysis and molecular ion peaks of com-
pounds 3a–j were consistent with the assigned structure.
4.2. Biological activity
4.2.1. In vitro antibacterial and antifungal activities
All the newly synthesized compounds 3a–j were screened
in vitro for their antimicrobial activities against clinically iso-
lated bacterial strains such as S. aureus, S. typhi, E. coli, P. vul-
garis, and B. subtilis by the cup-plate method. Ampicillin was
used as a reference standard drug. The noteworthy antibacte-
rial screening results of compounds 3a–j are depicted in the Ta-
ble 2. Compounds 3b, 3d, 3g, 3h–j displayed moderate activity
at 200 ug/mL against S. aureus whereas 3a, 3c, 3e and 3f exhib-
ited negligible activity. Among all the compounds, 3f and 3g
showed insigniﬁcant activity at 100 ug/mL, 200 ug/mL and
moderate activity at concentration 500 ug/mL against P. vul-
garis. Surprisingly, the microorganisms, E. coli, B. subtilis, S.
typhi displayed conﬂuent growth with no inhibition, this im-
plies the possibility that these microorganisms may possess
strong resistivity against 3a–j.
The compounds 3a–j tested against clinically isolatedC. albi-
cans, A. niger and P. chrysogenum strains, amphotericin B was
used as the standard drug. Compound 3d showed inhibition of
growth of microorganism at 200 ug/mL against A. niger and
P. chrysogenum, however, C. albicans displayed strong resistiv-
ity towards 3a–j. No signiﬁcant activity was observed at the
concentration of 10–100 ug/mL against all fungal strains, while
results obtained at 200 ug/mL are summarized in Table 3.
The study reveals that most of the synthesized compounds
possess low to moderate antimicrobial activities against P. vul-
garis, A. niger and P. chrysogenum suggesting that the presence
S456 S.S. Dave, A.M. Rahatgaonkarof electron withdrawing groups like (–Cl, –Br, –NO2) as substit-
uents at themeta and para positions in phenolic ring may atten-
uate the anti-microbial activity wherein MIC has been shifted
to higher concentration up to 500 ug/mL. Additionally, it
should be noted that these hybrid scaffolds when incorporated
with subunits like methyl and methoxy showed activity against
S. aureus. However, nitro group when amalgamated with halo-
gen in 3 g shows its virtue of activity against the strains S. aur-
eus. On the other hand, the same molecule couldn’t inhibit the
growth of P. vulgaris. Thus the selective antimicrobial behav-
iour of all the above said microorganisms towards the synthe-
sized molecules remains unexplored and the efﬁcacy of 3a–g
is proved to be independent of the nature of the substituents.
5. Conclusions
We have synthesized substituted 2-[2-amino-6-(2-chloroquino-
lin-3-yl)-5,6-dihydropyrimidin-4-yl]phenols (3a–j) with high
yields. All the synthesized compounds were evaluated for their
antibacterial and antifungal activities at conc 10–500 ug/mL.
These heterocycles accommodating both subunits i.e. quinoline
and pyrimidine are expected to prove the therapeutic relevance
and its utility in medicinal chemistry and drug development.
Ongoing research focuses on the same molecular hybrid tem-
plate with the incorporation of more effective substituents in
search of new speciﬁc and effective antimicrobial agents.
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